un dalles wird klarer.Der Deal steht kurz bevor.Klar ist er schon,es muß nur noch offiziell gemacht werden.Alles eine Frage von Stunden!!!Der kurs wird gerade eben noch gedrückt für die Explosion.Nennt es wie ihr es wollt,ich sage nur kauft und schaut dem Feuerwerk zu!
NEWS for BSX PRINT THIS PAGE BIG FONT SMALL FONT
BSX 32.38 -0.32
Today 5 Dy 1 Mo 3 Mo 1 Yr 5 Yr
Biophan CEO Michael Weiner to Present Today at Wall Street Analyst Forum in New York City, Talk to Be Webcast Live
ROCHESTER, N.Y.
Biophan Technologies, Inc.
Carolyn Hotchkiss, 585-214-2407
OR
Press Interviews:
Jennifer Gould, 212-843-8037
Company Chief to Discuss Market Growth Potential in Nanotechnology and Other Solutions in Multi-Billion Dollar Healthcare Sectors
Biophan Technologies, Inc. (OTCBB:BIPH), a developer of next-generation biomedical technology, has announced that Chief Executive Officer, Michael Weiner, will be presenting today at the Wall Street Analyst Forum, an annual conference that brings together analysts and other investment professionals in the financial community. The 16th annual forum runs February 28-March 2, at the Roosevelt Hotel in New York City.
Mr. Weiner will speak on Biophan's progress in improving medical equipment and devices, including making devices function effectively with MRI, and increasing the life span of implantable devices with a new battery with extended life, powered by body heat. His address is scheduled to begin at 11:40 am Eastern. To access the live webcast, visit www.analyst-conference.com and click on the link near the top of the page, labeled, " February 28th-March 2nd, 2005 Webcast." When the schedule of conference events appears, select " Wednesday, March 2," and then select, " Biophan Technologies." The simple webcast registration process will then initiate.
" The Wall Street Analyst Forum and the webcast provide an excellent platform for Biophan and other participating companies to reach interested investors and communicate the latest developments in our fields, as well as to describe important market conditions and opportunities," said Mr. Weiner.
Biophan and its licensors currently hold 108 patents, licenses or patent applications in a range of solutions, many of them involving advances in nanotechnology. The Company possesses a range of proprietary solutions that enable many medical devices and equipment, such as pacemakers and stents, to be used safely and/or effectively with Magnetic Resonance Imaging (MRI) devices. Many medical devices have been difficult to image, or unsafe with MRI, one of the most important imaging tools in medicine. Additional technology can extend the life of implanted devices by converting body heat into electrical power.
About The Wall Street Analyst Forum
The Wall Street Analyst Forum has been sponsoring analyst conferences in New York, Boston and London since 1989. They have involved 2,500 different presenting NYSE/NASDAQ/AMEX corporations and have been attended by more than 15,000 analysts and portfolio managers. Conferences have received coverage in major financial news outlets, including the Wall Street Journal, Barron's, CNBC, Bloomberg and others.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 108 U.S. patents, licenses, or applications. This total includes 32 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 68 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the " SEC" ). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Copyright © 2005 Business Wire. All reproduction, other than for an individual user's reference, is prohibited without prior written permission.
News Copyright © 2005 Interest!ALERT All rights reserved. |
Thread abonnieren
0.06 (4.29%) 
Basic Chart
